Paul C Herbert
Comment: I’ve looked through every page in the google results. There is nothing that constitutes notability. Having an article about oneself is not necessarily a good thing, and if he becomes notable, someone else will create an article. Cheers, In solidarity Wikipedian12512 (Talking is fine | contribs) 01:01, 11 November 2026 (UTC)
Paul C. Hébert
Paul C. Hébert is a Canadian scientist and health researcher, as well as a practicing palliative care and former critical care physician. He is a professor of medicine at the University of Ottawa and a clinician scientist at the Bruyère Health Research Institute. He was formerly a professor of medicine at Université de Montréal, where he also served as the Philanthropic Chair of the Fondation Héma-Québec–Bayer..[1]
He was appointed President[2] of the Canadian Institutes of Health Research (CIHR) for a five-year term, effective on January 2, 2025.
Early Life and Education
Hébert was born in Moncton, New Brunswick. He received a Doctor of Medicine (MD) from the University of Ottawa in 1986, a Master of Health Science (MHSc) from the University of British Columbia in 1993, and a Master of Health Leadership and Management from McGill University in 2021.
Personal Life
Hébert married Manon Gosselin in 1989, who passed away in 2009. He married Stephanie Hébert in 2011. He has three children. As of 2026, he lives in Ottawa, Ontario.
Research Contributions
Hébert’s research focuses on critical care medicine, transfusion medicine, and clinical trials.[3]
With Dr. Ian Stiell, he conducted trials of epinephrine and vasopressin in cardiac arrest, which primarily found no survival benefit and possible harm.[4]
Hébert was the lead author of the Transfusion Requirements in Critical Care (TRICC) trial[5], which randomized 838 critically ill adults to a restrictive (7 g/dL) or liberal (10 g/dL) hemoglobin threshold for transfusion. Thirty-day mortality did not differ significantly (18.7% vs 23.3%), and the restrictive strategy substantially reduced blood use. Patients in the restrictive group were less likely to die during their hospital stay and had slightly lower organ dysfunction[6]. The trial is credited with prompting a shift toward more restrictive transfusion practice[7][8]; a 10 g/dL threshold had been standard since the 1940s[9], and guidelines in the US, Australia, UK and much of Europe have since become more restrictive[10]. The study was published in the New England Journal of Medicine in 1999.
After the TRCC trial, he co-authored studies of blood processing and storage, including a 2003 JAMA study of Canada’s universal leukoreduction program, which was associated with lower adjusted in-hospital mortality[11], and the Age of Blood Evaluation (ABLE) trial[12]. It was published in the New England Journal of Medicine in 2015.
He also co-authored the Transfusion Requirements in Pediatric Intensive Care Units (TRIPICU) trial[13], which was published in the New England Journal of Medicine. He also contributed to the Myocardial Ischemia and Transfusion (MINT) trial[14], published in the New England Journal of Medicine in 2023.
Career History
2025-present: President, the Canadian Institute of Health Research[15]
2021-present: Professor of Medicine, University of Ottawa[16]
2020-2022: Chief Medical and Science Advisor, Canadian Red Cross[17]
2019-2020: Special Advisor to the CEO, Canadian Red Cross[18]
2016-2021: Philanthropic Chair, Héma Québec Bayer in Transfusion Medicine[19]
2013-2025: Senior Research Scientist, Centre de recherche du CHUM (CRCHUM)[20]
2013-2020: Professor of Medicine (Critical Care), Université de Montréal[21]
2013-2019: Physician-in-Chief, Centre hospitalier de l'Université de Montréal (CHUM)[22]
2013-2019: Chair, Canadian Critical Care Trials Group (CCCTG)[23]
2008-2010: Executive Director and Senior Advisor, Strategy on Patient Oriented Research, Canadian Institute of Health Research (CIHR)
2007-2011: Editor-in-Chief, The Canadian Medical Association Journal (CMAJ)[24]
1999-2013: Professor of Medicine (Critical Care and Epidemiology), University of Ottawa
1992-2013: Professor of Medicine, University of Ottawa
Recognition
Paul Hébert is a Fellow of the Canadian Academy of Health Sciences and a recipient of the Landsteiner-Alter Award for contributions to transfusion medicine[25]
References
- ↑ Government of Canada, Canadian Institutes of Health Research (2008-09-07). "President – Biography - CIHR". cihr-irsc.gc.ca. Retrieved 2026-11-10.
- ↑ Canada, Service (2015-10-13). "Not Found". www.canada.ca. Retrieved 2026-11-10.
- ↑ Government of Canada, Canadian Institutes of Health Research (2008-09-07). "President – Biography - CIHR". cihr-irsc.gc.ca. Retrieved 2026-11-10.
- ↑ Stiell, Ian G.; Hebert, Paul C.; Weitzman, Brian N.; Wells, George A.; Raman, Sankaranarayanan; Stark, Ryan M.; Higginson, Lyall A.J.; Ahuja, Jan; Dickinson, Garth E. (1992-10-08). "High-Dose Epinephrine in Adult Cardiac Arrest". New England Journal of Medicine. 327 (15): 1045–1050. doi:10.1056/NEJM199210083271502. ISSN 0028-4793.
- ↑ Hébert, Paul C.; Wells, George; Blajchman, Morris A.; Marshall, John; Martin, Claudio; Pagliarello, Giuseppe; Tweeddale, Martin; Schweitzer, Irwin; Yetisir, Elizabeth; null, null (1999-02-11). "A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care". New England Journal of Medicine. Massachusetts Medical Society. 340 (6): 409–417. doi:10.1056/NEJM199902113400601. ISSN 0028-4793.
- ↑ Nogrady, Bianca (2017-09). "Transfusion: Too much of a good thing". Nature. Nature Publishing Group. 549 (7673): S22–S23. doi:10.1038/549S22a. ISSN 1476-4687. Check date values in:
|date=(help) - ↑ Landro, Laura (2008-10-30). "Hospitals Seek to Limit Use of Transfusions - WSJ". Wall Street Journal. ISSN 0099-9660. Retrieved 2026-11-10.
- ↑ Nogrady, Bianca (2017-09). "Transfusion: Too much of a good thing". Nature. Nature Publishing Group. 549 (7673): S22–S23. doi:10.1038/549S22a. ISSN 1476-4687. Check date values in:
|date=(help) - ↑ Nogrady, Bianca (2017-09). "Transfusion: Too much of a good thing". Nature. Nature Publishing Group. 549 (7673): S22–S23. doi:10.1038/549S22a. ISSN 1476-4687. Check date values in:
|date=(help) - ↑ Nogrady, Bianca (2017-09). "Transfusion: Too much of a good thing". Nature. Nature Publishing Group. 549 (7673): S22–S23. doi:10.1038/549S22a. ISSN 1476-4687. Check date values in:
|date=(help) - ↑ Hébert, Paul C.; Fergusson, Dean; Blajchman, Morris A.; Wells, George A.; Kmetic, Andrew; Coyle, Doug; Heddle, Nancy; Germain, Marc; Goldman, Mindy; Toye, Baldwin; Schweitzer, Irwin; vanWalraven, Carl; Devine, Dana; Sher, Graham D.; Leukoreduction Study Investigators (2003-04-16). "Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions". JAMA. 289 (15): 1941–1949. doi:10.1001/jama.289.15.1941. ISSN 0098-7484. PMID 12697796.
- ↑ Lacroix, Jacques; Hébert, Paul C.; Fergusson, Dean A.; Tinmouth, Alan; Cook, Deborah J.; Marshall, John C.; Clayton, Lucy; McIntyre, Lauralyn; Callum, Jeannie; Turgeon, Alexis F.; Blajchman, Morris A.; Walsh, Timothy S.; Stanworth, Simon J.; Campbell, Helen; Capellier, Gilles (2015-04-09). "Age of Transfused Blood in Critically Ill Adults". New England Journal of Medicine. Massachusetts Medical Society. 372 (15): 1410–1418. doi:10.1056/NEJMoa1500704. ISSN 0028-4793.
- ↑ Lacroix, Jacques; Hébert, Paul C.; Hutchison, James S.; Hume, Heather A.; Tucci, Marisa; Ducruet, Thierry; Gauvin, France; Collet, Jean-Paul; Toledano, Baruch J.; Robillard, Pierre; Joffe, Ari; Biarent, Dominique; Meert, Kathleen; Peters, Mark J.; TRIPICU Investigators (2007-04-19). "Transfusion strategies for patients in pediatric intensive care units". The New England Journal of Medicine. 356 (16): 1609–1619. doi:10.1056/NEJMoa066240. ISSN 1533-4406. PMID 17442904.
- ↑ Carson, Jeffrey L.; Brooks, Maria Mori; Hébert, Paul C.; Goodman, Shaun G.; Bertolet, Marnie; Glynn, Simone A.; Chaitman, Bernard R.; Simon, Tabassome; Lopes, Renato D.; Goldsweig, Andrew M.; DeFilippis, Andrew P.; Abbott, J. Dawn; Potter, Brian J.; Carrier, Francois Martin; Rao, Sunil V. (2023-12-27). "Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia". New England Journal of Medicine. Massachusetts Medical Society. 389 (26): 2446–2456. doi:10.1056/NEJMoa2307983. ISSN 0028-4793. PMC 10837004 Check
|pmc=value (help). PMID 37952133 Check|pmid=value (help). - ↑ Canada, Service (2015-10-13). "Not Found". www.canada.ca. Retrieved 2026-11-10.
- ↑ "Dr. Paul Hébert". Faculty of Medicine. Retrieved 2026-11-10.
- ↑ Government of Canada, Canadian Institutes of Health Research (2008-09-07). "President – Biography - CIHR". cihr-irsc.gc.ca. Retrieved 2026-11-10.
- ↑ Government of Canada, Canadian Institutes of Health Research (2008-09-07). "President – Biography - CIHR". cihr-irsc.gc.ca. Retrieved 2026-11-10.
- ↑ "Bruyère Health - Research | Paul Hebert". www.bruyere.org. Retrieved 2026-11-10.
- ↑ "Bruyère Health - Research | Paul Hebert". www.bruyere.org (in français). Retrieved 2026-11-10.
- ↑ "Researcher". La recherche - Université de Montréal. Retrieved 2026-11-10.
- ↑ "Paul Hébert, MD, MHSc, FRCPC, FCAHS | CMHF". www.cdnmedhall.ca (in français). Retrieved 2026-11-10.
- ↑ "Bruyère Health - Research | Paul Hebert". www.bruyere.org. Retrieved 2026-11-10.
- ↑ "Bruyère Health - Research | Paul Hebert". www.bruyere.org. Retrieved 2026-11-10.
- ↑ Government of Canada, Canadian Institutes of Health Research (2008-09-07). "President – Biography - CIHR". cihr-irsc.gc.ca. Retrieved 2026-11-10.
This article "Paul C Herbert" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Paul C Herbert. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
